Profile data is unavailable for this security.
About the company
Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical system and the Ion endoluminal system. The Company's products and related services enable physicians and healthcare providers to access minimally invasive care. The systems consist of a surgeon console or consoles, a patient-side cart, a vision system, and instruments and accessories. Its da Vinci products consist of five categories, such as da Vinci surgical systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems and da Vinci Endoscopes. It also provides a suite of systems, learning, and services offerings. Its Ion endoluminal system extends its commercial offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung. Its services include readiness support, maintenance support, perioperative consulting, customer hospital analytics, and market consulting optimization.
- Revenue in USD (TTM)6.22bn
- Net income in USD1.32bn
- Incorporated1995
- Employees12.12k
- LocationIntuitive Surgical Inc1020 Kifer RoadSUNNYVALE 94086United StatesUSA
- Phone+1 (408) 523-2100
- Fax+1 (408) 523-1390
- Websitehttps://www.intuitivesurgical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DexCom, Inc. | 2.91bn | 341.20m | 44.21bn | 7.50k | 142.85 | 20.73 | 88.93 | 15.19 | 0.8009 | 0.8009 | 6.84 | 5.52 | 0.5636 | 3.05 | 4.74 | 387,973.30 | 6.61 | 6.48 | 8.79 | 7.85 | 65.19 | 66.58 | 11.73 | 11.04 | 1.83 | 1,012.75 | 0.4878 | 0.00 | 18.84 | 32.28 | 57.31 | 43.79 | 40.77 | -- |
| Edwards Lifesciences Corp | 5.38bn | 1.52bn | 49.44bn | 17.30k | 33.45 | 8.55 | 29.76 | 9.19 | 2.44 | 2.44 | 8.62 | 9.55 | 0.641 | 1.35 | 8.79 | 311,121.40 | 18.12 | 16.32 | 20.65 | 19.04 | 79.96 | 76.32 | 28.28 | 24.43 | 2.17 | -- | 0.0931 | 0.00 | 2.86 | 9.40 | 1.25 | 11.64 | 8.57 | -- |
| Becton Dickinson and Co | 18.74bn | 1.49bn | 69.48bn | 77.00k | 47.36 | 2.73 | 18.60 | 3.71 | 5.18 | 5.30 | 65.34 | 89.72 | 0.3519 | 3.12 | 8.40 | 243,350.70 | 2.96 | 2.21 | 3.42 | 2.51 | 44.78 | 45.78 | 8.41 | 6.55 | 0.5995 | 6.32 | 0.3925 | 86.56 | -1.36 | 9.31 | 2.05 | 8.45 | 6.00 | -- |
| Boston Scientific Corporation | 12.68bn | 642.00m | 71.29bn | 45.00k | 111.21 | 4.05 | 40.03 | 5.62 | 0.446 | 0.446 | 8.81 | 12.26 | 0.392 | 2.26 | 6.77 | 281,822.20 | 2.16 | 2.75 | 2.47 | 3.28 | 69.00 | 69.03 | 5.52 | 7.01 | 1.02 | 8.20 | 0.3371 | 0.00 | 6.68 | 6.99 | -34.82 | -7.83 | 5.50 | -- |
| Intuitive Surgical, Inc. | 6.22bn | 1.32bn | 88.02bn | 12.12k | 68.81 | 7.97 | 50.68 | 14.15 | 3.65 | 3.65 | 17.19 | 31.55 | 0.4691 | 2.74 | 7.21 | 513,382.80 | 10.14 | 12.86 | 11.28 | 14.29 | 67.44 | 68.30 | 21.61 | 27.14 | 3.77 | -- | 0.00 | 0.00 | 8.97 | 14.67 | -22.43 | 5.99 | 22.79 | -- |
| Medtronic PLC | 30.77bn | 4.06bn | 105.34bn | 95.00k | 26.03 | 2.05 | 15.50 | 3.42 | 3.04 | 3.04 | 23.06 | 38.67 | 0.331 | 2.07 | 5.43 | 323,915.80 | 4.40 | 5.08 | 5.04 | 5.72 | 66.72 | 68.46 | 13.29 | 15.45 | 1.39 | 23.05 | 0.3527 | 62.61 | 5.21 | 1.30 | 43.97 | 4.58 | 1.76 | 7.94 |
| Stryker Corp | 18.45bn | 2.36bn | 106.42bn | 51.00k | 45.49 | 6.40 | 31.71 | 5.77 | 6.17 | 6.17 | 48.27 | 43.88 | 0.516 | 1.86 | 5.60 | 361,745.10 | 6.59 | 6.43 | 7.77 | 7.59 | 63.14 | 64.87 | 12.78 | 12.79 | 0.9964 | -- | 0.4399 | 44.45 | 7.84 | 8.19 | 18.25 | 4.94 | -0.3367 | 10.77 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2022 | 27.94m | 7.98% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2022 | 20.88m | 5.96% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 16.61m | 4.74% |
| SSgA Funds Management, Inc.as of 31 Dec 2022 | 14.89m | 4.25% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2022 | 7.44m | 2.12% |
| AllianceBernstein LPas of 31 Dec 2022 | 7.37m | 2.10% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2022 | 6.73m | 1.92% |
| Edgewood Management LLCas of 31 Dec 2022 | 6.64m | 1.90% |
| Geode Capital Management LLCas of 31 Dec 2022 | 6.38m | 1.82% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2022 | 5.76m | 1.64% |
